ADVERTISEMENT
Search

 

Press Releases

 

13

Jul

2022

New Federal Guidance confuses an already complicated landscape for pharmacists

Author: James Keagy

Today, in response to the U.S. Supreme Court recent decision in Dobbs v Jackson Women’s Health Organization, the U.S. Department of Health and Human Services’ Office for Civil Rights (OCR) released guidance for pharmacies that sets forth their obligations under federal civil rights laws, conflicting with some state laws, and raises concerns for our nation's pharmacies and pharmacists.

Comments (0)
Number of views (8482)
Article rating: No rating

6

Jul

2022

Breaking: FDA permits pharmacists to prescribe Paxlovid to treat COVID-19

Author: James Keagy

Today, after months of effort by APhA and other stakeholders, FDA has updated the EUA for the COVID-19 oral antiviral, Paxlovid, to permit pharmacists to order and prescribe Paxlovid under certain conditions.

Comments (0)
Number of views (15105)
Article rating: No rating

2

Jun

2022

APhA Changes Executive Leadership

Ilisa Bernstein appointed Interim CEO

The Board of Trustees of the American Pharmacists Association announced today that Ilisa Bernstein, PharmD, JD, FAPhA, has been named Interim CEO, effective immediately. Bernstein’s appointment follows the departure of Scott Knoer, PharmD, MS, as Executive Vice-President and CEO.

Comments (0)
Number of views (17524)
Article rating: No rating

26

May

2022

APhA statement on Texas Mass Shooting

WASHINGTON, DC—The American Pharmacists Association (APhA) is deeply saddened by the horrific mass shooting in Uvalde, Texas, elementary school in which a gunman took the lives of at least 19 young children and two dedicated teachers.

Comments (0)
Number of views (2872)
Article rating: No rating

2

May

2022

APhA appreciates CMS’ elimination of retroactive DIR fees

Though more actions are needed to address PBMs’ harmful business practices

Author: Renee Kalu

WASHINGTON, D.C.—CMS has issued a final rule eliminating Part D plans’ and PBMs’ use of retroactive direct and indirect remuneration (DIR) fees beginning on January 1, 2024 (contract year 2024). The American Pharmacists Association (APhA) and many of its members submitted comments to CMS on the proposal. APhA appreciates CMS’ efforts to end the uncertainty and lack of drug cost transparency at the pharmacy caused by retroactive DIR fees.

Comments (0)
Number of views (8152)
Article rating: No rating
RSS
First1011121314151719
Advertisement
Advertisement
Advertisement
Advertisement
ADVERTISEMENT